Site-specific SIR of cancer among patients with a hospital-based diagnosis of a venous ulcer, Denmark, 1982-2012
| . | <1 y of Follow-up . | ≥1 y of Follow-up . | ||||
|---|---|---|---|---|---|---|
| Observed . | Expected . | SIR (95% CI) . | Observed . | Expected . | SIR (95% CI) . | |
| All cancers | 655 | 469 | 1.40 (1.29-1.51) | 3274 | 3083 | 1.06 (1.03-1.10) |
| Hematological cancers | 50 | 27 | 1.83 (1.36-2.42) | 212 | 174 | 1.22 (1.06-1.39) |
| Non-Hodgkin lymphoma | 25 | 11 | 2.25 (1.45-3.32) | 84 | 73 | 1.15 (0.92-1.42) |
| Leukemia | 19 | 11 | 1.77 (1.06-2.76) | 95 | 67 | 1.42 (1.15-1.73) |
| Multiple myeloma | 6 | 4.7 | 1.29 (0.47-2.81) | 27 | 29 | 0.92 (0.61-1.34) |
| Hodgkin lymphoma | 0 | 0.69 | — | 6 | 4.1 | 1.46 (0.54-3.18) |
| Nonhematological cancers | 605 | 442 | 1.37 (1.26-1.48) | 3062 | 2909 | 1.05 (1.02-1.09) |
| Tongue | 4 | 1.1 | 3.53 (0.96-9.04) | 15 | 7.8 | 1.93 (1.08-3.18) |
| Penis | 2 | 0.57 | 3.49 (0.42-12.61) | 9 | 3.8 | 2.35 (1.08-4.47) |
| Bone and articular cartilage | 1 | 0.33 | 3.04 (0.08-16.94) | 5 | 1.9 | 2.70 (0.88-6.30) |
| Liver | 12 | 4.1 | 2.94 (1.52-5.14) | 50 | 26 | 1.92 (1.43-2.54) |
| Anus and anal canal | 3 | 1.1 | 2.64 (0.54-7.70) | 8 | 7.4 | 1.09 (0.47-2.14) |
| Renal pelvis | 3 | 1.2 | 2.58 (0.53-7.54) | 4 | 7.1 | 0.56 (0.15-1.44) |
| Connective and soft tissue | 5 | 2.0 | 2.53 (0.82-5.90) | 13 | 13 | 1.02 (0.54-1.74) |
| Cervix | 9 | 4.0 | 2.26 (1.04-4.30) | 18 | 21 | 0.86 (0.51-1.35) |
| Malignant melanoma | 21 | 9.6 | 2.18 (1.35-3.33) | 66 | 68 | 0.97 (0.75-1.24) |
| Pancreas | 28 | 13 | 2.16 (1.44-3.12) | 80 | 80 | 0.99 (0.79-1.24) |
| Esophagus | 9 | 5.0 | 1.81 (0.83-3.44) | 42 | 33 | 1.26 (0.91-1.70) |
| Kidney | 13 | 7.2 | 1.80 (0.96-3.09) | 55 | 45 | 1.21 (0.91-1.58) |
| Pleura | 2 | 1.2 | 1.73 (0.21-6.26) | 7 | 7.8 | 0.90 (0.36-1.85) |
| Nonmelanoma skin cancer | 185 | 108 | 1.72 (1.48-1.98) | 754 | 771 | 0.98 (0.91-1.05) |
| Nonmelanoma skin cancer of the leg | 40 | 5.0 | 8.08 (5.77-11.00) | 46 | 38 | 1.22 (0.90-1.63) |
| Other ill-defined or unspecified sites | 11 | 6.7 | 1.65 (0.82-2.95) | 38 | 37 | 1.03 (0.73-1.41) |
| Lung, bronchus, and trachea | 72 | 49 | 1.48 (1.16-1.86) | 330 | 321 | 1.03 (0.92-1.15) |
| Metastasis and unspecified cancer in lymph nodes (primary unknown) | 18 | 12 | 1.46 (0.86-2.30) | 117 | 76 | 1.54 (1.27-1.85) |
| Gallbladder and bile ducts | 5 | 3.7 | 1.34 (0.43-3.12) | 31 | 21 | 1.48 (1.00-2.10) |
| Mouth | 3 | 2.3 | 1.30 (0.27-3.80) | 26 | 15 | 1.75 (1.14-2.56) |
| Brain | 5 | 3.9 | 1.29 (0.42-3.01) | 23 | 26 | 0.89 (0.56-1.34) |
| Urinary bladder | 16 | 14 | 1.18 (0.67-1.92) | 99 | 84 | 1.18 (0.96-1.44) |
| Prostate | 44 | 37 | 1.18 (0.86-1.58) | 262 | 273 | 0.96 (0.85-1.08) |
| Breast | 56 | 49 | 1.15 (0.87-1.49) | 339 | 313 | 1.08 (0.97-1.20) |
| Ovary and fallopian tube | 9 | 7.9 | 1.13 (0.52-2.15) | 38 | 47 | 0.81 (0.57-1.11) |
| Larynx | 3 | 2.8 | 1.08 (0.22-3.15) | 22 | 18 | 1.23 (0.77-1.86) |
| Small intestine | 1 | 1.0 | 0.98 (0.02-5.46) | 5 | 6.6 | 0.76 (0.25-1.77) |
| Colon | 38 | 43 | 0.88 (0.62-1.20) | 262 | 267 | 0.98 (0.87-1.11) |
| Uterus | 8 | 10 | 0.78 (0.34-1.55) | 94 | 63 | 1.49 (1.21-1.83) |
| External female genitalia | 1 | 1.7 | 0.61 (0.02-3.38) | 11 | 9.8 | 1.12 (0.56-2.00) |
| Stomach | 5 | 10 | 0.50 (0.16-1.16) | 63 | 54 | 1.16 (0.89-1.48) |
| Rectum | 7 | 20 | 0.35 (0.14-0.73) | 107 | 123 | 0.87 (0.72-1.05) |
| Tonsil and pharynx | 0 | 2.1 | — | 26 | 15 | 1.68 (1.10-2.46) |
| Endocrine glands and related structure | 0 | 1.4 | — | 12 | 8.8 | 1.36 (0.70-2.38) |
| Testis | 0 | 0.53 | — | 6 | 2.9 | 2.08 (0.76-4.54) |
| . | <1 y of Follow-up . | ≥1 y of Follow-up . | ||||
|---|---|---|---|---|---|---|
| Observed . | Expected . | SIR (95% CI) . | Observed . | Expected . | SIR (95% CI) . | |
| All cancers | 655 | 469 | 1.40 (1.29-1.51) | 3274 | 3083 | 1.06 (1.03-1.10) |
| Hematological cancers | 50 | 27 | 1.83 (1.36-2.42) | 212 | 174 | 1.22 (1.06-1.39) |
| Non-Hodgkin lymphoma | 25 | 11 | 2.25 (1.45-3.32) | 84 | 73 | 1.15 (0.92-1.42) |
| Leukemia | 19 | 11 | 1.77 (1.06-2.76) | 95 | 67 | 1.42 (1.15-1.73) |
| Multiple myeloma | 6 | 4.7 | 1.29 (0.47-2.81) | 27 | 29 | 0.92 (0.61-1.34) |
| Hodgkin lymphoma | 0 | 0.69 | — | 6 | 4.1 | 1.46 (0.54-3.18) |
| Nonhematological cancers | 605 | 442 | 1.37 (1.26-1.48) | 3062 | 2909 | 1.05 (1.02-1.09) |
| Tongue | 4 | 1.1 | 3.53 (0.96-9.04) | 15 | 7.8 | 1.93 (1.08-3.18) |
| Penis | 2 | 0.57 | 3.49 (0.42-12.61) | 9 | 3.8 | 2.35 (1.08-4.47) |
| Bone and articular cartilage | 1 | 0.33 | 3.04 (0.08-16.94) | 5 | 1.9 | 2.70 (0.88-6.30) |
| Liver | 12 | 4.1 | 2.94 (1.52-5.14) | 50 | 26 | 1.92 (1.43-2.54) |
| Anus and anal canal | 3 | 1.1 | 2.64 (0.54-7.70) | 8 | 7.4 | 1.09 (0.47-2.14) |
| Renal pelvis | 3 | 1.2 | 2.58 (0.53-7.54) | 4 | 7.1 | 0.56 (0.15-1.44) |
| Connective and soft tissue | 5 | 2.0 | 2.53 (0.82-5.90) | 13 | 13 | 1.02 (0.54-1.74) |
| Cervix | 9 | 4.0 | 2.26 (1.04-4.30) | 18 | 21 | 0.86 (0.51-1.35) |
| Malignant melanoma | 21 | 9.6 | 2.18 (1.35-3.33) | 66 | 68 | 0.97 (0.75-1.24) |
| Pancreas | 28 | 13 | 2.16 (1.44-3.12) | 80 | 80 | 0.99 (0.79-1.24) |
| Esophagus | 9 | 5.0 | 1.81 (0.83-3.44) | 42 | 33 | 1.26 (0.91-1.70) |
| Kidney | 13 | 7.2 | 1.80 (0.96-3.09) | 55 | 45 | 1.21 (0.91-1.58) |
| Pleura | 2 | 1.2 | 1.73 (0.21-6.26) | 7 | 7.8 | 0.90 (0.36-1.85) |
| Nonmelanoma skin cancer | 185 | 108 | 1.72 (1.48-1.98) | 754 | 771 | 0.98 (0.91-1.05) |
| Nonmelanoma skin cancer of the leg | 40 | 5.0 | 8.08 (5.77-11.00) | 46 | 38 | 1.22 (0.90-1.63) |
| Other ill-defined or unspecified sites | 11 | 6.7 | 1.65 (0.82-2.95) | 38 | 37 | 1.03 (0.73-1.41) |
| Lung, bronchus, and trachea | 72 | 49 | 1.48 (1.16-1.86) | 330 | 321 | 1.03 (0.92-1.15) |
| Metastasis and unspecified cancer in lymph nodes (primary unknown) | 18 | 12 | 1.46 (0.86-2.30) | 117 | 76 | 1.54 (1.27-1.85) |
| Gallbladder and bile ducts | 5 | 3.7 | 1.34 (0.43-3.12) | 31 | 21 | 1.48 (1.00-2.10) |
| Mouth | 3 | 2.3 | 1.30 (0.27-3.80) | 26 | 15 | 1.75 (1.14-2.56) |
| Brain | 5 | 3.9 | 1.29 (0.42-3.01) | 23 | 26 | 0.89 (0.56-1.34) |
| Urinary bladder | 16 | 14 | 1.18 (0.67-1.92) | 99 | 84 | 1.18 (0.96-1.44) |
| Prostate | 44 | 37 | 1.18 (0.86-1.58) | 262 | 273 | 0.96 (0.85-1.08) |
| Breast | 56 | 49 | 1.15 (0.87-1.49) | 339 | 313 | 1.08 (0.97-1.20) |
| Ovary and fallopian tube | 9 | 7.9 | 1.13 (0.52-2.15) | 38 | 47 | 0.81 (0.57-1.11) |
| Larynx | 3 | 2.8 | 1.08 (0.22-3.15) | 22 | 18 | 1.23 (0.77-1.86) |
| Small intestine | 1 | 1.0 | 0.98 (0.02-5.46) | 5 | 6.6 | 0.76 (0.25-1.77) |
| Colon | 38 | 43 | 0.88 (0.62-1.20) | 262 | 267 | 0.98 (0.87-1.11) |
| Uterus | 8 | 10 | 0.78 (0.34-1.55) | 94 | 63 | 1.49 (1.21-1.83) |
| External female genitalia | 1 | 1.7 | 0.61 (0.02-3.38) | 11 | 9.8 | 1.12 (0.56-2.00) |
| Stomach | 5 | 10 | 0.50 (0.16-1.16) | 63 | 54 | 1.16 (0.89-1.48) |
| Rectum | 7 | 20 | 0.35 (0.14-0.73) | 107 | 123 | 0.87 (0.72-1.05) |
| Tonsil and pharynx | 0 | 2.1 | — | 26 | 15 | 1.68 (1.10-2.46) |
| Endocrine glands and related structure | 0 | 1.4 | — | 12 | 8.8 | 1.36 (0.70-2.38) |
| Testis | 0 | 0.53 | — | 6 | 2.9 | 2.08 (0.76-4.54) |
SIRs computed according to Danish national cancer incidence rates according to 5-year age groups, sex, and 5-year intervals of year of diagnosis. CIs were derived using Byar approximation, assuming that the observed number of cases in a specific category follows a Poisson distribution. We used exact 95% CIs when the observed number of cancers was <10. Only cancers with 5 observed outcomes overall are presented.
—, not applicable.